<DOC>
	<DOCNO>NCT01209221</DOCNO>
	<brief_summary>This placebo-controlled , randomize , observer-blind , dose-ascending study investigate safety , tolerability , pharmacokinetics pharmacodynamics single multiple dos RO5271983 healthy volunteer . Healthy volunteer randomize receive either single oral dose RO5271983 placebo SAD part multiple oral dos RO5271983 placebo MAD part . The anticipated time study treatment approximately 14 week SAD part 8 week MAD part .</brief_summary>
	<brief_title>A Single Ascending And Multiple Ascending Dose Study RO5271983 Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy volunteer , 1865 year age Body Mass Index ( BMI ) 18 32 kg/m2 , inclusive In SAD , females subject must surgically sterile postmenopausal past year ; MAD female may childbearing potential must use 2 method highly effective contraception A history clinically relevant cardiovascular , gastrointestinal , hepatic , renal , endocrine , pulmonary , neurological , psychiatric , allergic skin disease Clinical significant abnormality laboratory test result Symptoms infectious disease include upper respiratory tract infection within one month study start history recurrent infection Smokers &gt; 5 cigarettes/day within 3 month prior admission unable stop smoking study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>